Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bright

Showing results (181-190 of 194) with videos related to

Pageof 20
Sort By:
Rhinology|September 23, 2022
Rhino-orbito-cerebral mucormycosis: patient characteristics in pre-COVID-19 and COVID-19 periodL M Cherian, L Varghese, V Rupa, et al.
Advances in Genomics and Genetics|April 30, 2019
Frequency of frontotemporal dementia gene variants in <i>C9ORF72</i>, <i>MAPT</i>, and <i>GRN</i> in academic versus commercial laboratory cohortsNatasha Zr Steele, Alison R Bright, Suzee E Lee, et al.
Journal of Clinical Pharmacology|July 17, 2001
Immunological and molecular analysis of the sentinel lymph node: a potential approach to predict outcome, tailor therapy, and optimize parameters for tumor vaccine developmentS L Meijer, A Dols, H M Hu, et al.
Nature Communications|February 15, 2020
A case report of multiple primary prostate tumors with differential drug sensitivityScott Wilkinson, Stephanie A Harmon, Nicholas T Terrigino, et al.
Human Mutation|October 16, 2015
A Standardized DNA Variant Scoring System for Pathogenicity Assessments in Mendelian DisordersIzabela Karbassi, Glenn A Maston, Angela Love, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2020
Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic ResponseFatima Karzai, Stephanie M Walker, Scott Wilkinson, et al.
Medrxiv : the Preprint Server for Health Sciences|February 19, 2024
Localized high-risk prostate cancer harbors an androgen receptor low subpopulation susceptible to HER2 inhibitionScott Wilkinson, Anson T Ku, Rosina T Lis, et al.
European Urology|March 31, 2021
Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal TherapyScott Wilkinson, Huihui Ye, Fatima Karzai, et al.
Journal for Immunotherapy of Cancer|March 25, 2026
Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancerChennan Li, Ravi A Madan, Min-Jung Lee, et al.
The Journal of Clinical Investigation|September 4, 2025
Localized high-risk prostate cancer harbors an androgen receptor activity-low subpopulation susceptible to HER2 inhibitionScott Wilkinson, Anson T Ku, Rosina T Lis, et al.
Pageof 20

Showing results (181-190 of 194) with videos related to

Sort By:
Pageof 20
Rhinology|September 23, 2022
Rhino-orbito-cerebral mucormycosis: patient characteristics in pre-COVID-19 and COVID-19 periodL M Cherian, L Varghese, V Rupa, et al.
Advances in Genomics and Genetics|April 30, 2019
Frequency of frontotemporal dementia gene variants in <i>C9ORF72</i>, <i>MAPT</i>, and <i>GRN</i> in academic versus commercial laboratory cohortsNatasha Zr Steele, Alison R Bright, Suzee E Lee, et al.
Journal of Clinical Pharmacology|July 17, 2001
Immunological and molecular analysis of the sentinel lymph node: a potential approach to predict outcome, tailor therapy, and optimize parameters for tumor vaccine developmentS L Meijer, A Dols, H M Hu, et al.
Nature Communications|February 15, 2020
A case report of multiple primary prostate tumors with differential drug sensitivityScott Wilkinson, Stephanie A Harmon, Nicholas T Terrigino, et al.
Human Mutation|October 16, 2015
A Standardized DNA Variant Scoring System for Pathogenicity Assessments in Mendelian DisordersIzabela Karbassi, Glenn A Maston, Angela Love, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2020
Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic ResponseFatima Karzai, Stephanie M Walker, Scott Wilkinson, et al.
Medrxiv : the Preprint Server for Health Sciences|February 19, 2024
Localized high-risk prostate cancer harbors an androgen receptor low subpopulation susceptible to HER2 inhibitionScott Wilkinson, Anson T Ku, Rosina T Lis, et al.
European Urology|March 31, 2021
Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal TherapyScott Wilkinson, Huihui Ye, Fatima Karzai, et al.
Journal for Immunotherapy of Cancer|March 25, 2026
Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancerChennan Li, Ravi A Madan, Min-Jung Lee, et al.
The Journal of Clinical Investigation|September 4, 2025
Localized high-risk prostate cancer harbors an androgen receptor activity-low subpopulation susceptible to HER2 inhibitionScott Wilkinson, Anson T Ku, Rosina T Lis, et al.
Pageof 20